QHSLab repurchases $470K promissory note with 1.57M shares, extinguishing related-party debt

QHSLab, Inc.

Repurchased and cancelled promissory note held by MedScience; outstanding principal and interest $470,529 as of Dec 31, 2025.
Issued 1,568,432 shares of common stock as consideration; shares issued in private transaction exempt from registration.
CEO Troy Grogan is minority shareholder of MedScience; received no personal distribution from transaction.
Company states repurchase simplifies capital structure and eliminates related-party debt obligation.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

QHSLab, Inc. issued 1,568,432 shares of common stock to MedScience Research Group, Inc. for cancellation of indebtedness.

Security: common stock
Shares: 1,568,432 shares
Purchaser: MedScience Research Group, Inc.
Consideration: cancellation of indebtedness

Exact text from the filing

the Company issued an aggregate of 1,568,432 shares of its common stock, par value $0.0001 per share (the “Shares”), as directed by MedScience

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

QHSLab, Inc. terminated Repurchase Agreement with MedScience Research Group, Inc..

Action: termination
Counterparty: MedScience Research Group, Inc.

Exact text from the filing

QHSLab, Inc. (the “Company”) consummated a Note Repurchase Agreement (the “Repurchase Agreement”) with MedScience Research Group, Inc., a Florida corporation (“MedScience”).

View on SEC.gov

Browse all equity issuances →

QHSLab, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-003438

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.